A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001) (MODIFY I)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Merck Sharp & Dohme Corp.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01241552
First received: November 12, 2010
Last updated: June 20, 2014
Last verified: June 2014
  Purpose

This study will investigate whether: 1) treatment with MK-3415A in addition to standard of care (SOC) antibiotic therapy will decrease Clostridium difficile infection (CDI) recurrence as compared to treatment with MK-6072 or MK-3415, 2) treatment with MK-3415A, MK-6072, or MK-3415, in addition to SOC antibiotic therapy will decrease CDI recurrence as compared to placebo, and 3) MK-3415A, MK-6072, and MK-3415 will be generally well tolerated in participants receiving SOC therapy for CDI as compared to placebo.


Condition Intervention Phase
Clostridium Difficile Infection
Biological: MK-3415
Biological: MK-6072
Biological: MK-3415A
Biological: Placebo
Drug: SOC
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Number of participants with Clostridium difficile infection (CDI) recurrence [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic Clostridium difficile following clinical cure of the initial CDI episode


Secondary Outcome Measures:
  • Number of participants with Global Cure [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Global Cure is defined as the clinical cure of the initial CDI episode and no CDI recurrence through Week 12. Clinical cure is defined as participants received ≤ 16 days of SOC therapy and have no diarrhea (≤2 loose stools per 24 hours) for two consecutive days following completion of SOC therapy for the initial CDI episode.

  • Number of participants with CDI recurrence in those with clinical cure of the initial CDI episode [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 1600
Study Start Date: October 2011
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MK-3415 + SOC
Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI
Biological: MK-3415
A single IV infusion of MK-3415 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A)
Drug: SOC
Standard of care (SOC) for CDI will be prescribed for 10 to 14 days beginning on the day of study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
Experimental: MK-6072 + SOC
Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI
Biological: MK-6072
A single infusion of MK-6072 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
Drug: SOC
Standard of care (SOC) for CDI will be prescribed for 10 to 14 days beginning on the day of study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
Experimental: MK-3415A + SOC
Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI
Biological: MK-3415A
A single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A and 10mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
Drug: SOC
Standard of care (SOC) for CDI will be prescribed for 10 to 14 days beginning on the day of study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
Placebo Comparator: Placebo + SOC
Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI
Biological: Placebo
A single IV infusion of normal saline (0.9% sodium chloride)
Drug: SOC
Standard of care (SOC) for CDI will be prescribed for 10 to 14 days beginning on the day of study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • participant has a confirmed diagnosis of CDI as defined by: a. diarrhea, as defined by passage of 3 or more loose stools in 24 or fewer hours, AND b. A positive test for toxigenic C. difficile from a stool collected no more than 7 days before study infusion.
  • participant must be receiving SOC therapy for CDI. SOC therapy is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
  • participant is highly unlikely to become pregnant or to impregnate a partner since they meet at least one of the following criteria: a. A female participant who is not of reproductive potential is eligible without requiring the use of contraception. A female participant who is not of reproductive potential is defined as: one who has either (1) reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle stimulating hormone (FSH) levels in the postmenopausal range as determined by the local laboratory, or 12 months of spontaneous amenorrhea); (2) 6 weeks post surgical bilateral oophorectomy with or without hysterectomy; or (3) bilateral tubal ligation. Spontaneous amenorrhea does not include cases for which there is an underlying disease that causes amenorrhea (e.g. anorexia nervosa). b. A participant who is of reproductive potential agrees to remain abstinent or use (or have their partner use) 2 acceptable methods of birth control starting at enrollment and through the 12 Week study period. Acceptable methods of birth control are: intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, vasectomy and any registered and marketed hormonal contraceptives that contain an estrogen and/or a progestational agent (including oral, subcutaneous, intrauterine, or intramuscular agents)
  • participant or legal representative must have voluntarily agreed to participate by providing written informed consent after the nature of the study has been fully explained.

Exclusion Criteria:

  • participant with an uncontrolled chronic diarrheal illness such that their normal 24-hour bowel movement habit is 3 or more loose stools.
  • participant with a planned surgery for CDI within 24 hours.
  • participant has a positive pregnancy test in the 48 hours before the infusion or is unwilling to undergo pregnancy testing if a pre-menopausal female who is not sterilized and therefore has the potential to bear a child.
  • participant is breast-feeding or plans to breast-feed prior to the completion of the 12-week study period.
  • A female participant who plans to donate ova prior to the completion of the 12-week study period, or a male participant who is planning to impregnate or provide sperm donation prior to the completion of the 12-week study period.
  • participant has previously participated in this study, has previously received MK-3415 or MK- 6072 (either alone or in combination), has received a C. difficile vaccine, or has received another experimental monoclonal antibody against C. difficile toxin A or B.
  • participant plans to donate blood and/or blood products within 6 months following the infusion.
  • participant has received immune globulin within 6 months prior to receipt of the infusion or is planning to receive immune globulin prior to the completion of the 12-week study period.
  • treatment with SOC therapy is planned for longer than 14 days.
  • participant has received more than a 24-hour regimen of cholestyramine, colestimide, rifaximin, or nitazoxanide within 14 days prior to receipt of the infusion or is planning to receive these medications prior to the completion of the 12-week study period.
  • participant plans to take medications that are given to decrease gastrointestinal peristalsis, such as loperamide (Imodium™) or diphenoxylate hydrochloride/atropine sulfate (LOMOTIL™), at any time during the 14 days following infusion. Participants receiving opioid medications at the onset of diarrhea may be included if they are on a stable dose or if there is anticipation of a dose decrease or cessation of use.
  • participant plans to take the probiotic Saccharomyces boulardii or receive fecal transplant therapy, or any other therapies that have been demonstrated to decrease CDI recurrences at any time following infusion (Day 1) and through the completion of the 12-week study period.
  • participant has received another investigational study agent within the previous 30 days, or is currently participating in or scheduled to participate in any other clinical trial with an investigational agent during the 12-week study period.
  • participant is not expected to survive for 72 hours.
  • participant has any other condition that, in the opinion of the investigator, would jeopardize the safety or rights of the participant participating in the study, would make it unlikely for the participant to complete the study, or would confound the results of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01241552

Contacts
Contact: Toll Free Number 1-888-577-8839

  Hide Study Locations
Locations
United States, Alabama
Call for Information (Investigational Site 0093) Recruiting
Birmingham, Alabama, United States, 35249
United States, Arizona
Call for Information (Investigational Site 0048) Recruiting
Phoenix, Arizona, United States, 85008
Call for Information (Investigational Site 0110) Recruiting
Phoenix, Arizona, United States, 85012
Call for Information (Investigational Site 0145) Recruiting
Phoenix, Arizona, United States, 85054
United States, California
Call for Information (Investigational Site 0076) Recruiting
Chula Vista, California, United States, 91911
Call for Information (Investigational Site 0060) Recruiting
La Mesa, California, United States, 91941
Call for Information (Investigational Site 0043) Recruiting
Mission Hills, California, United States, 91345
Call for Information (Investigational Site 0142) Recruiting
Sacramento, California, United States, 95817
Call for Information (Investigational Site 0041) Recruiting
Sacramento, California, United States, 95825
United States, Delaware
Call for Information (Investigational Site 0038) Recruiting
Newark, Delaware, United States, 19713
United States, District of Columbia
Call for Information (Investigational Site 0068) Recruiting
Washington, District of Columbia, United States, 20007
Call for Information (Investigational Site 0071) Recruiting
Washington, District of Columbia, United States, 20422
United States, Florida
Call for Information (Investigational Site 0213) Recruiting
Gainesville, Florida, United States, 32610
Call for Information (Investigational Site 0067) Recruiting
Jacksonville, Florida, United States, 32224
Call for Information (Investigational Site 0147) Recruiting
Miami, Florida, United States, 33136
Call for Information (Investigational Site 0143) Recruiting
Miami, Florida, United States, 33155
Call for Information (Investigational Site 0214) Recruiting
Orange Park, Florida, United States, 32073
United States, Idaho
Call for Information (Investigational Site 0046) Recruiting
Idaho Falls, Idaho, United States, 83404
Call for Information (Investigational Site 0082) Recruiting
Idaho Falls, Idaho, United States, 83404
United States, Illinois
Call for Information (Investigational Site 0081) Recruiting
Chicago, Illinois, United States, 60637
Call for Information (Investigational Site 0065) Recruiting
Springfield, Illinois, United States, 62703
Call for Information (Investigational Site 0113) Recruiting
Springfield, Illinois, United States, 62781
United States, Kansas
Call for Information (Investigational Site 0091) Recruiting
Topeka, Kansas, United States, 66606
United States, Maryland
Call for Information (Investigational Site 0042) Recruiting
Baltimore, Maryland, United States, 21224
United States, Massachusetts
Call for Information (Investigational Site 0059) Recruiting
Boston, Massachusetts, United States, 02111
United States, Michigan
Call for Information (Investigational Site 0001) Recruiting
Detroit, Michigan, United States, 48201
Call for Information (Investigational Site 0105) Recruiting
Detroit, Michigan, United States, 48202
Call for Information (Investigational Site 0203) Recruiting
Detroit, Michigan, United States, 48201
Call for Information (Investigational Site 0099) Recruiting
Royal Oak, Michigan, United States, 48073
United States, Missouri
Call for Information (Investigational Site 0057) Recruiting
Kansas City, Missouri, United States, 64131
Call for Information (Investigational Site 0112) Recruiting
Kansas City, Missouri, United States, 64108
United States, Montana
Call for Information (Investigational Site 0087) Recruiting
Butte, Montana, United States, 59701
United States, New Jersey
Call for Information (Investigational Site 0136) Recruiting
Neptune, New Jersey, United States, 07753
United States, New York
Call for Information (Investigational Site 0158) Recruiting
Flushing, New York, United States, 11355
Call for Information (Investigational Site 0056) Recruiting
New Hyde Park, New York, United States, 11040
Call for Information (Investigational Site 0045) Recruiting
New York, New York, United States, 10016
Call for Information (Investigational Site 0044) Recruiting
Rochester, New York, United States, 14642
United States, North Carolina
Call for Information (Investigational Site 0050) Recruiting
Greenville, North Carolina, United States, 27834
United States, Ohio
Call for Information (Investigational Site 0085) Recruiting
Centerville, Ohio, United States, 45459
Call for Information (Investigational Site 0146) Recruiting
Cincinnati, Ohio, United States, 45219
Call for Information (Investigational Site 0039) Recruiting
Columbus, Ohio, United States, 43215
Call for Information (Investigational Site 0101) Recruiting
Lima, Ohio, United States, 45801
Call for Information (Investigational Site 0212) Recruiting
Mentor, Ohio, United States, 44060
United States, Pennsylvania
Call for Information (Investigational Site 0053) Recruiting
Hershey, Pennsylvania, United States, 17033
Call for Information (Investigational Site 0083) Recruiting
Pittsburgh, Pennsylvania, United States, 15213
United States, South Dakota
Call for Information (Investigational Site 0090) Recruiting
Rapid City, South Dakota, United States, 57701
United States, Tennessee
Call for Information (Investigational Site 0107) Recruiting
Nashville, Tennessee, United States, 37232
United States, Texas
Call for Information (Investigational Site 0052) Recruiting
Houston, Texas, United States, 77030
United States, Utah
Call for Information (Investigational Site 0144) Recruiting
Salt Lake City, Utah, United States, 84124
United States, Virginia
Call for Information (Investigational Site 0049) Recruiting
Richmond, Virginia, United States, 23249
Call for Information (Investigational Site 0205) Recruiting
Richmond, Virginia, United States, 23298
United States, Washington
Call for Information (Investigational Site 0104) Recruiting
Everett, Washington, United States, 98201
Call for Information (Investigational Site 0157) Recruiting
Seattle, Washington, United States, 98104
Call for Information (Investigational Site 0209) Recruiting
Seattle, Washington, United States, 98195
Australia
Merck Sharp & Dohme Recruiting
North Ryde, Australia
Contact: Gary Jankelowitz    61 2 8988 8246      
Austria
MSD ýterreich GmbH Recruiting
Vienna, Austria
Contact: Karl Boegl    43 126044130      
Belgium
MSD Belgium BVBA/SPRL Recruiting
Brussels, Belgium
Contact: Danny D'Hulster    32 23734310      
Brazil
MSD Brasil Recruiting
Sao Paulo, Brazil
Contact: Ricardo Germano    55 11 51897942      
Canada, Quebec
Merck Canada Recruiting
Kirkland, Quebec, Canada, H9H 3L1
Contact: Medical Information Centre / Centre de l'information medicale de Merck Canada    514-428-8600 / 1-800-567-2594      
Chile
Merck Sharp & Dohme (I.A.) Corp. Recruiting
Santiago, Chile
Contact: Maria Elena Azara Hernandez    56 2 6558958      
Colombia
MDS Colombia SAS Recruiting
Bogota, Colombia
Contact: Francesca Carvajal    57 1219109011090      
Czech Republic
Merck Sharp and Dohme s.r.o. Recruiting
Praha, Czech Republic
Contact: Simona Martinkova    420 233010213      
Denmark
Merck Sharp & Dohme Recruiting
Glostrup, Denmark
Contact: Gert Andersen    45 44824475      
Germany
Merck Sharp & Dohme GmbH Recruiting
Haar, Germany
Contact: German Medical Information Center    49 800 673 673 673      
Israel
Merck Sharp & Dohme Co. Ltd. Recruiting
Hod Hasharon, Israel
Contact: Ofer Sharon    972 9 9539310      
Italy
MSD Italia S.r.l. Recruiting
Rome, Italy
Contact: Patrizia Nardini    39 06 361911      
Mexico
MSD Recruiting
Mexico City, Mexico
Contact: Juan Marques    52 55254819608      
New Zealand
Merck Sharp & Dohme (New Zealand) Ltd., Recruiting
Wellington, New Zealand
Contact: Gary Jankelowitz    61 2 8988 8246      
Portugal
Merck Sharp & Dohme Lda. Recruiting
Paco D'arcos, Portugal
Contact: Ana Maria Nogueira    351-21-4465890      
South Africa
MSD (Pty) LTD South Africa Recruiting
Midrand, South Africa
Contact: Khanyi Mzolo    27 11 655 3140      
Spain
Merck Sharp and Dohme de Espana S.A. Recruiting
Madrid, Spain
Contact: Cesar Sanz Rodriguez    34 913210600      
United Kingdom
Merck Sharp & Dohme Ltd. Recruiting
Hoddesdon, United Kingdom
Contact: Paul Robinson    44 1992452396      
Sponsors and Collaborators
Merck Sharp & Dohme Corp.
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01241552     History of Changes
Other Study ID Numbers: 3415A-001
Study First Received: November 12, 2010
Last Updated: June 20, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Merck Sharp & Dohme Corp.:
Clostridium difficile
recurrent Clostridium difficile
vancomycin
metronidazole
monoclonal antibody
Clostridium difficile infection (CDI)

Additional relevant MeSH terms:
Clostridium Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Anti-Bacterial Agents
Antibiotics, Antitubercular
Antibodies
Immunoglobulins
Antibodies, Monoclonal
Metronidazole
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antitubercular Agents
Immunologic Factors
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Antiprotozoal Agents
Antiparasitic Agents

ClinicalTrials.gov processed this record on July 28, 2014